Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Astolfi

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Neuropeptides|March 9, 2002
Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonistR Cirillo, M Astolfi, B Conte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cellsP Corradini, C Voena, C Tarella, et al.
Experimental Hematology|February 13, 2001
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patientsM Ladetto, S Sametti, J W Donovan, et al.
Leukemia|December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaM Ladetto, F Zallio, S Vallet, et al.
Leukemia|February 16, 2007
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patientsI Ricca, A Rocci, D Drandi, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Neuropeptides|March 9, 2002
Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonistR Cirillo, M Astolfi, B Conte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cellsP Corradini, C Voena, C Tarella, et al.
Experimental Hematology|February 13, 2001
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patientsM Ladetto, S Sametti, J W Donovan, et al.
Leukemia|December 26, 2001
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphomaM Ladetto, F Zallio, S Vallet, et al.
Leukemia|February 16, 2007
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patientsI Ricca, A Rocci, D Drandi, et al.
Pageof 6